- C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
- C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
- C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
- C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
- C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
- C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals
- C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
On Wednesday, C4 Therapeutics Inc (CCCC:NSQ) closed at 6.45, 508.49% above the 52 week low of 1.06 set on Dec 06, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.83 |
---|---|
High | 7.29 |
Low | 6.36 |
Bid | 6.35 |
Offer | 6.50 |
Previous close | 6.79 |
Average volume | 1.26m |
---|---|
Shares outstanding | 68.81m |
Free float | 60.83m |
P/E (TTM) | -- |
Market cap | 467.19m USD |
EPS (TTM) | -2.67 USD |
Data delayed at least 15 minutes, as of May 08 2024 21:00 BST.
More ▼